ADOCIA Shares Surge 26.46% Over the Week, Boosted by Analyst Recommendation
The Lyon-based company specializing in diabetes and obesity treatments experienced a particularly dynamic week, closing at €9.75 on Friday, October 10. This weekly increase of 26.46% is in stark contrast to the downturns of the CAC 40 and SBF 120, which both fell by approximately 1.7% over the same period.
The week was marked by a significant acceleration on Thursday, October 9, where the stock jumped 35.40% to reach €10.48, before slightly retracting to €9.75 the following day. Trading volumes skyrocketed on this occasion, with more than 2 million shares traded on Thursday, approximately 11% of the company's capital, compared to less than 300,000 shares in previous sessions. This surge is part of a particularly robust medium-term dynamic, with the stock showing a growth of 148.7% over three months and 81.56% over a year, a considerable gap compared to the Parisian indices which have increased by about 4.6% over twelve months. On Friday, despite a 7% decline from the previous day's high, volumes remained strong with 1.36 million shares traded, indicating sustained investor interest.
Sharp Rise Following Analyst Coverage
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
This sharp rise followed the initiation of coverage by Invest Securities on Thursday, October 9, with the analysis firm setting a buy recommendation and a price target of €17.90. This target price represents an upside potential of over 80% compared to the closing price on Friday, which largely explains the surge in trading volumes observed. Analysts justify their position by the significant potential of the company in the drug delivery technology segment applied to diabetes and obesity, a rapidly expanding market. The peak reached on Thursday at €10.48 now constitutes a technical resistance level to watch, while the support identified at €7.30 remains relatively distant, offering a comfortable margin in case of consolidation.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -95,8 %
Net income: -8,6 millions d'euros
Guidance from the release
visibilité financière maintenue jusqu'au début du deuxième trimestre 2027 ; incertitude significante sur la continuité d'exploitation
Risks mentioned
Consommation de trésorerie de 10,1 M€ au premier semestre 2026
Horizon de financement limité au début du deuxième trimestre 2027
Chiffre d'affaires semestriel en forte baisse, de 1 031 K€ à 43 K€
Opportunities identified
Résultats positifs de Phase 3 de BioChaperone® Lispro en Chine et dépôt d'AMM en préparation
Trois études de faisabilité BioChaperone® positives avec de grandes pharmas, deux en discussions avancées
AdOral® Sema breveté et libre d'exploitation alors que le semaglutide devient libre de droit en 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.